DexCom (NASDAQ:DXCM) Price Target Raised to $103.00
DexCom (NASDAQ:DXCM – Get Free Report) had its target price boosted by investment analysts at Canaccord Genuity Group from $99.00 to $103.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the medical device company’s stock. Canaccord Genuity Group’s price target points to a […]
More Stories
Barclays Revises US Recession Outlook After China Trade Truce
By Katabella Roberts Barclays no longer expects the United States economy to fall into a recession later this year and...
Patel Says FBI Is Moving Out of Washington Headquarters
By Jack Phillips FBI Director Kash Patel on Friday morning confirmed that the FBI is leaving its Washington headquarters, known...
Verizon Ends DEI Programs Amid FCC Scrutiny Ahead of $20 Billion Frontier Bid
By Tom Ozimek Verizon Communications has announced the end of its Diversity, Equity, and Inclusion (DEI) initiatives, aligning itself with...
2025 Preakness Stakes Preview: What You Need to Know
By Ross Kelly Nearly two weeks ago, Sovereignty galloped to victory at the most-watched Kentucky Derby in over 35 years....
Common Security Mistakes Made By Businesses and How to Avoid Them
How secure is your business against cyberattacks? Alarmingly, around 50% of small businesses have no cybersecurity defenses in place to...
Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Baird Financial Group Inc.
Baird Financial Group Inc. lowered its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 90.8% during the fourth...